How promising is th RCH-01/Replicel treatment? Is there any new info that suggests it will be as successful as it claims? What other promising treatments are close? Technology 4/26/2019
The conversation is about the potential of the RCH-01/Replicel hair loss treatment and its lack of updates since 2013, with the user expressing hope for its success and considering using Minoxidil, finasteride, and dermarolling in the meantime. Other treatments mentioned as promising are Breezula and Tsuji.
View this post in the Community →
Similar Community Posts Join
5 / 12 resultscommunity Shiseido/Replicel RCH-01 trial results were finally shared online
The Shiseido/Replicel RCH-01 trial results were disappointing and ineffective. Users expressed skepticism and frustration, suggesting alternatives like Tsuji or simply accepting baldness.
community Target Area Hair Count (TAHC) increase comparasion of all future treatments in clinical trial phases
Finasteride, Minoxidil, Bioneer CosmeRNA, Technoderma, Kintor, Hope, Breezula, and Follicum treatments showed increases in hair count, with Technoderma showing the highest increase at 24.3 hairs/cm². Amplifica has not yet published results.
community "After ten years of scientific research, Japanese personal care player, Shiseido has patented its RepliCel Hair-01 (RCH-01) hair regeneration technology."
The conversation discusses Shiseido's RepliCel Hair-01 technology for hair regeneration, which aims to stop hair loss with minimal regrowth. Treatments mentioned include Minoxidil, finasteride, and RU58841.
Related Research
6 / 14 results
research Experimental and Early Investigational Drugs for Androgenetic Alopecia
New hair loss treatments may include topical medications, injections, and improved transplant methods.
research Regenerative Medicine Approaches for Engineering a Human Hair Follicle
New treatments for hair loss show promise, including plasma, stem cells, and hair-stimulating complexes, but more research is needed to fully understand them.
research Social Interest Data as a Proxy for Off-Label Performance-Enhancing Drug Use: Implications and Clinical Considerations
Clinicians should use social and prescription data to track trends in performance-enhancing drug use.